Kurma Companions’ new fund is the enterprise capital agency’s fourth and largest. Earlier Kurma investments have led to exits that embrace the acquisitions of Corlieve Therapeutics, Emergence Therapeutics, and Amolyt Pharma.
The publish VC Agency Kurma Companions Closes €215M Fund in Pursuit of ‘Disruptive Therapeutic Options’ appeared first on MedCity Information.
